What should be done for a patient who develops palpitations after increasing Vyvanse (lisdexamfetamine) to 30 mg?

Management of Palpitations After Increasing Vyvanse to 30mg

Reduce the Vyvanse dose back to the previous tolerated level or discontinue it temporarily, assess cardiovascular status including blood pressure and heart rate, and evaluate for underlying cardiac disease before considering further dose escalation. 1, 2, 3

Immediate Actions

Dose Adjustment

• Decrease the dose immediately back to the previously tolerated level (typically 20mg if that was the starting dose) or hold the medication temporarily 1, 2, 4
• Amphetamines, including lisdexamfetamine (Vyvanse), are known to cause cardiovascular effects including palpitations, increased heart rate, and blood pressure elevation 1, 2, 4

Cardiovascular Assessment

• Measure vital signs including blood pressure and pulse at rest 3
• Obtain an ECG to evaluate for arrhythmias, QT prolongation, or other abnormalities 3
• The FDA label specifically warns about increased blood pressure and heart rate as common effects requiring monitoring 3

Risk Stratification

Screen for Serious Cardiac Disease

• Evaluate for contraindications including structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease 3
• Vyvanse should be avoided in patients with known serious heart disease due to risk of sudden cardiac death 3
• Ask specifically about: chest pain, shortness of breath, syncope, or family history of sudden cardiac death 3

Common vs. Concerning Palpitations

• Mild palpitations with modest heart rate increases (2-5 bpm above baseline) are common and may be tolerable 5
• Concerning features include: palpitations with chest pain, dyspnea, presyncope/syncope, or pulse ≥100 bpm 6, 7, 5
• In clinical trials, pulse outliers (≥100 bpm) occurred in 3.3-8.5% of patients on lisdexamfetamine 5

Management Algorithm

If Palpitations Are Mild and Vital Signs Normal

• Reduce to 20mg daily (the lower end of the starting dose range) and monitor for 1-2 weeks 8
• The recommended starting dose for Vyvanse is 20-30mg daily, with titration by 10mg weekly 8
• If tolerated at lower dose, consider slower titration (every 2 weeks instead of weekly) 8

If Palpitations Are Moderate or Vital Signs Abnormal

• Hold Vyvanse temporarily until cardiovascular evaluation is complete 3
• Consider alternative ADHD treatments including non-stimulants (atomoxetine, guanfacine, clonidine, bupropion, or viloxazine) 8, 9
• If stimulant therapy is still desired after clearance, consider methylphenidate-based medications which may have different cardiovascular profiles 8

If Serious Cardiac Symptoms Present

• Discontinue Vyvanse immediately and refer for urgent cardiology evaluation 3
• Do not restart stimulant therapy until cardiac clearance is obtained 3

Important Caveats

Monitoring Requirements

• Regular cardiovascular monitoring is advisable for all patients on stimulants, even those without baseline cardiac disease 5
• Blood pressure and pulse should be checked at baseline, after dose changes, and periodically during maintenance 3

Drug Interactions

• Review for medications that may exacerbate cardiovascular effects: other sympathomimetics, MAO inhibitors (contraindicated), serotonergic agents, or drugs affecting urinary pH 3

Patient Education

• Instruct patient to report immediately: chest pain, shortness of breath, fainting, or worsening palpitations 3
• Avoid caffeine and other stimulants which can compound cardiovascular effects 1, 2, 4